Physician profile
Michael Polcari
NPI 1568807378
$38,689.96
in general payments reported to CMS, 2019-2025
39 companies · $5,285 in 2025
The $5,285 reported for 2025 was more than what 84% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,148 · 2020: $845 · 2021: $1,600 · 2022: $2,292 · 2023: $23K · 2024: $4,139 · 2025: $5,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $13K · Education: $156 · Travel and Lodging: $91.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,825.00 |
| Food and Beverage | $12,731.82 |
| Education | $156.16 |
| Travel and Lodging | $91.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $21,832.20 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Csl Behring | $2,482.33 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Astrazeneca Pharmaceuticals LP | $2,407.04 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $1,742.06 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,581.46 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $1,427.26 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $1,242.33 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Optinose US, INC. | $889.89 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $820.22 | 2022-2025 | |
| Blueprint Medicines Corporation | $743.72 | 2022-2025 | Ayvakit |
| Amgen INC. | $615.59 | 2020-2025 | Tezspire |
| Pfizer INC. | $547.29 | 2020-2025 | |
| Leo Pharma INC. | $536.28 | 2022-2025 | Adbry, Anzupgo |
| Grifols USA, LLC | $296.54 | 2020-2024 | Xembify |
| Pharming Healthcare, INC. | $166.32 | 2019-2025 | Ruconest |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gc Biopharma USA, INC. | $166.20 | 2024-2025 | Alyglo, Alyglo |
| Organon LLC | $148.42 | 2025 | Vtama |
| Kaleo, INC. | $141.12 | 2019-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $134.91 | 2025 | Neffy |
| Lilly USA, LLC | $127.67 | 2024-2025 | Ebglyss |
| Genentech, INC. | $87.91 | 2023 | Xolair |
| Biocryst US Sales Co., LLC | $69.72 | 2024-2025 | Orladeyo |
| Insmed, INC. | $65.31 | 2025 | Brinsupri, Arikayce |
| Cycle Pharmaceuticals INC | $64.92 | 2024-2025 | Sajazir |
| Mylan Specialty L.P. | $52.40 | 2021-2024 | Yupelri |
| Abbvie INC. | $49.06 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $48.16 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $44.30 | 2025 | Xhance |
| Adma Biomanufacturing LLC | $26.48 | 2020-2021 | |
| Alk-Abello, INC | $23.45 | 2020 | |
| Ionis Pharmaceuticals, INC. | $22.79 | 2025 | Dawnzera |
| Galderma Laboratories, L.P. | $17.90 | 2025 | Nemluvio |
| Hikma Pharmaceuticals USA | $14.97 | 2025 | Ryaltris |
| Eyevance Pharmaceuticals LLC | $14.19 | 2021 | |
| Merck Sharp & Dohme LLC | $13.62 | 2023 | |
| Incyte Corporation | $13.60 | 2025 | Opzelura |
| Shire North American Group INC | $12.33 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Polcari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.